|
|
Volumn 362, Issue 9392, 2003, Pages
|
|
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
PACLITAXEL;
PLATINUM DERIVATIVE;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
FEMALE;
HUMAN;
MORTALITY;
NOTE;
OVARY TUMOR;
STATISTICS;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CLINICAL TRIALS;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
OVARIAN NEOPLASMS;
PACLITAXEL;
PLATINUM COMPOUNDS;
TREATMENT OUTCOME;
|
|
EID: 17144473539
PISSN: None
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/s0140-6736(03)14603-x Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
